ACAD Q3 2022 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$131M-0.7% YoY

Gross Profit

$129M98.4% margin

Operating Income

-$31M-23.6% margin

Net Income

-$27M-20.8% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

-2.9%

Cash Flow

Operating Cash Flow

-$727,000

Free Cash Flow

-$727,000

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$602M

Total Liabilities

$177M

Stockholders' Equity

$426M

Cash & Equivalents

$155M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$131M	$132M	-0.7%
Gross Profit	$129M	$125M	+2.9%
Operating Income	-$31M	-$15M	-101.7%
Net Income	-$27M	-$14M	-88.0%